TARS — Tarsus Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1819790 ·
Last close
$72.81
Market Cap
$3.20B
52W High
$73.51
52W Low
$53.89
ADV30
877,792
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 173,912,000 | 161,799,000 | -19,908,000 | -18,551,000 | 611,142,000 | 204,595,000 | 264,410,000 |
| Mar 2026 | 162,054,000 | 152,658,000 | -6,122,000 | -6,967,000 | 581,135,000 | 102,192,000 | 232,184,000 |
| Dec 2025 | 151,668,000 | 140,741,000 | -7,976,000 | -8,373,000 | 562,158,000 | 183,641,000 | 218,732,000 |
| Sep 2025 | 118,697,000 | 110,388,000 | -14,529,000 | -12,585,000 | 534,561,000 | 112,724,000 | 199,479,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$74,158,000
Investing CF
$23,847,000
Financing CF
$9,380,000
CapEx
$-18,155,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-452,146,000
Inventory
$4,377,000
Receivables
$98,309,000
ST Investments
$245,095,000
EBIT TTM
$-31,215,000
Pretax Income TTM
$-39,349,000
Interest Exp TTM
$8,134,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$606,331,008
EBITDA
$-46,195,000
Free Cash Flow
$67,467,872
Enterprise Value
$2,834,242,048
Total Cash
$449,689,984
Total Debt
$88,811,000
Shares Out
43,882,996
Trailing EPS
$-1.07
Book Value
$8.11
ROE
-13.7%
ROA
-5.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 451,360,000 | -70,969,000 | -66,418,000 | 562,158,000 | 218,732,000 | — | -12,451,000 |
| Dec 2024 | 182,953,000 | -120,569,000 | -115,554,000 | 376,991,000 | 152,457,000 | — | -83,027,000 |
| Dec 2023 | 17,447,000 | -143,158,000 | -135,893,000 | 265,491,000 | 68,503,000 | — | -117,493,000 |
| Dec 2022 | 25,816,000 | -62,712,000 | -62,091,000 | 227,863,000 | 34,963,000 | — | -49,030,000 |
TTM Snapshot
Revenues TTM
$51,229,000
NetIncome TTM
$-100,776,000
OpCashFlow TTM
$0
Assets (Latest)
$376,991,000
Forward EPS
$2.33
Max Pain — expiry 2026-10-16
max pain strike: $62.50 · spot: $71.96 · call oi: 6,099 · put oi: 6,266Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc. | $2.93B | $28.33 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.65B | $8.06 | — |
| DNLI | Denali Therapeutics Inc. | $3.87B | $24.20 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.08B | $25.55 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.47B | $9.68 | — |
News headlines (Yahoo Finance, 1h cache)
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
2026-08-13 23:14 · Yahoo
Tarsus (TARS) Q2 2026 Earnings Call Transcript
2026-08-13 18:32 · Yahoo
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
2026-08-07 17:04 · Yahoo
Tarsus joins Stargardt race to market with $800m Alkeus takeover
2026-08-07 12:13 · Yahoo
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M
2026-08-06 14:07 · Yahoo
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
2026-08-06 11:03 · Yahoo
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
2026-08-06 11:01 · Yahoo
Tarsus Pharmaceuticals (TARS) Replaces Its Commercial Chief While iRenix Talks Continue
2026-07-16 02:11 · Yahoo
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
2026-07-13 20:05 · Yahoo
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
2026-07-08 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.